HK Stock Market Move | GENFLEET-B (02595) rose more than 9% after completing the first case of a study on the treatment of advanced solid tumors with GFH375 combination therapy.

GENFLEET-B (02595) fell by more than 8% in the afternoon, but rose by over 9% near the close of trading. As of the time of writing, it has risen 6.71% to HK$28.3, with a turnover of HK$445.83 million. On the news front, Jingfang Pharmaceutical announced that its oral high-activity and highly selective small molecule KRAS G12D (ON/OFF) inhibitor GFH375, in combination therapy for the treatment of KRAS G12D mutant advanced solid tumors in a phase Ib/II study, has enrolled its first patient at Peking University Cancer Hospital. This study obtained approval for clinical trials from the National Medical Products Administration in September this year, involving the combination therapy of GFH375 with cetuximab or chemotherapy, with the GFH375 combination chemotherapy regimen being a first-line therapy for pancreatic ductal adenocarcinoma (PDAC). It is noteworthy that the data of GFH375 as a monotherapy for KRAS G12D mutant PDAC patients will be presented in a breakthrough study abstract (LBA) and oral presentation at the ESMO 2025 Annual Meeting on October 19th. The oral presentation will be delivered by Professor Zhou Aiping from the Cancer Hospital of the Chinese Academy of Medical Sciences, with the presentation titled "Efficacy and Safety of GFH375 in the Treatment of KRAS G12D Mutant PDAC Patients in Advanced Disease". The presentation will focus on the study data of PDAC patients in the 600 mgQD (RP2D) dose group, showing notable efficacy of GFH375 in treating PDAC patients with manageable safety.